The rationale for combining STING agonists with DNA damaging agents needs to be further verified since it is not known if the increased resistance of cancer cells to genotoxic stress caused by the STING pathway activation (Gaston et al. 2016) will overcome the significance of antitumor immune response induction related to increased expression of NKG2D ligand (Lam et al. 2014) and secretion of cytokines that facilitate tissue repair and antitumor-T cell priming (Gaston et al. 2016; Xia et al. 2016a). This evidence concerns the gene STING1 and cancer.